VJHemOnc is committed to improving our service to you

VJVirtual | Zanubrutinib plus rituximab in first-line MCL therapy

VJHemOnc is committed to improving our service to you

Constantine Tam

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, of The Peter MacCallum Cancer Centre, Melbourne, Australia, outlines the phase III study (NCT04002297) comparing the efficacy of zanubrutinib, a BTK inhibitor, with rituximab against standard treatment in first-line mantle-cell lymphoma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter